Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

hat the final procedural step for French pricing and reimbursement of Esbriet had been completed.  The company expects the commercial launch of Esbriet in France in the second half of November 2012. 
  • On October 2, 2012, InterMune announced that Health Canada had approved Esbriet for the treatment of mild to moderate IPF in adult patients.  IPF affects approximately 5,000 to 8,000 Canadians.  InterMune expects to make Esbriet available in Canada starting January 1, 2013 with a commercial organization of approximately 18 to 20 in Canada at the time of launch, including a field force of 10.  Approximately one-third of IPF patients in Canada are covered by private insurance and InterMune expects to secure coverage from substantially all of the private insurance plans in the first half of 2013.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients and reimbursement from these plans is typically secured within 12 to 18 months of marketing approval.
  • InterMune today announced that the company secured Esbriet pricing and reimbursement in Belgium effective December 1, 2012 and plans to launch Esbriet there in early 2013. The Belgian annualized price of Esbriet is €30,240, or $36,533 at current exchange rates. 
  • InterMune has now concluded successful pricing and reimbursement discussions in nine European countries: Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway and Sweden.
  • InterMune today provided an update on the on-going pricing and reimbursement processes for Esbriet in the various European countries:
  • Italy – The company announced today that Esbriet successfully passed the Italian Technical-Scientific Commission review in October.  The company expects to conclude the pricing and reimbursement process in December of 2012 and plans to launch Esbriet in Italy as soon as possible after the process is successfully conc
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
    (Date:12/19/2014)... Arlington, MA (PRWEB) December 18, 2014 ... products for ophthalmology and wound care. The National Eye ... has awarded LayerBio a Phase I SBIR grant to ... , Cataracts are the most common cause of vision ... cause of blindness worldwide. According to Dr. Ken Mandell, ...
    (Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
    (Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
    Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
    ... 2007 versus $5.2 Million ... for Q3 of 2006, -- Gross profit increases 102% to $2.6 Million for ... Million ... Debt to Equity, BEIJING, Nov. 23 /Xinhua-PRNewswire/ -- China Biopharmaceuticals,Holdings, Inc. (OTC Bulletin Board: ...
    ... Bristol-,Myers Squibb Company (NYSE: BMY ) ... terminating their license agreement for the development of,vinflunine, ... of,advanced or metastatic bladder cancer and other tumor ... licensed to Bristol-Myers Squibb,in 2004 for specific territories. ...
    ... November 22 ,Essilor yesterday cancelled 700,000 shares as ... dilutive impact of stock option and performance,share plans., ... of Directors authorized the,granting of 930,740 stock options ... potentially lead to the issuance of up to,1,507,004 ...
    Cached Biology Technology:China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 2China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 3China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 4China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 5China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 6China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 7
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
    (Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
    (Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
    Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
    ... of stem cells such as regenerating damaged tissues or ... the past decade. While these types of applications are exciting, ... most immediate impact of stem cells on human health will ... new drugs. , The ability to generate stem cells by ...
    ... preservative, may slow or stop squamous cell head and neck ... What makes this particularly good news is that the Food ... as safe for human consumption decades ago, says Yvonne Kapila, ... Michigan School of Dentistry. This means that ...
    ... release is available in German . ... is a promising anode material for photoelectro-chemical cells (PEC) because ... to the solar spectrum. Although it has the potential of ... lower than that of other metal oxides. This is due ...
    Cached Biology News:The role of stem cells in developing new drugs 2Common food preservative may slow, even stop tumor growth 2The hunt for electron holes 2The hunt for electron holes 3
    ... Rabbit monoclonal [EP282Y] to Asparagine ... all tested applications). ... corresponding to residues in the ... Entrez GeneID: ...
    Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
    Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
    Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
    Biology Products: